Baptist Health Louisville

Brian W Kaebnick

Principal Investigator

Karin Cryan

Want to join the trial?

Choose a location to contact our Clinical Trial Coordinator and to discuss potential opportunities.

Email Coordinator
Flare-FT2: FlowTriever Pulmonary Embolectomy Clinical Study-FlowTriever2 (FLARE-FT2)

The FLARE-FT2 confirmatory study is a prospective, single-arm, multicenter study of the FlowTriever2 Catheter.

Learn more at

Eligibility Criteria

Inclusion Criteria:

Clinical signs and symptoms consistent with acute PE
PE symptom duration ≤ 14 days
CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)
RV/LV ratio of ≥ 0.9 (NOTE: Enrollment qualification assessment based on Investigator's interpretation of RV/LV ratio)
Systolic blood pressure ≥ 90 mmHg (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mmHg with fluids)
Stable heart rate < 130 BPM prior to procedure
Patient is deemed medically eligible for interventional procedure(s), per institutional guidelines and/or clinical judgment.
FlowTriever2 Catheter enters the vasculature

Exclusion Criteria:

Thrombolytic use within 30 days of baseline CTA
Pulmonary hypertension with peak pulmonary artery pressure > 70 mmHg by right heart catheterization
Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg
FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%
Hematocrit < 28% (NOTE: hematocrit required within 6 hours of index procedure)
Platelets < 100,000/μL
Serum creatinine > 1.8 mg/dL
INR > 3
Major trauma Injury Severity Score (ISS) > 15
Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months
Cardiovascular or pulmonary surgery within last 7 days
Actively progressing cancer
Known bleeding diathesis or coagulation disorder
Left bundle branch block
History of severe or chronic pulmonary arterial hypertension
History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
History of uncompensated heart failure
History of underlying lung disease that is oxygen dependent
History of chest irradiation
History of heparin-induced thrombocytopenia (HIT) Any contraindication to systemic or therapeutic doses heparin or anticoagulants
Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominately chronic clot, or non-clot embolus)
Life expectancy of < 90 days, as determined by Investigator
Female who is pregnant or nursing
Current participation in another investigational drug or device treatment study